AR097226A1 - Prodrogas de rebamipida, método para prepararlas y uso de las mismas - Google Patents
Prodrogas de rebamipida, método para prepararlas y uso de las mismasInfo
- Publication number
- AR097226A1 AR097226A1 ARP130102268A ARP130102268A AR097226A1 AR 097226 A1 AR097226 A1 AR 097226A1 AR P130102268 A ARP130102268 A AR P130102268A AR P130102268 A ARP130102268 A AR P130102268A AR 097226 A1 AR097226 A1 AR 097226A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heterocycloalkyl
- heteroaryl
- radical
- Prior art date
Links
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 28
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 10
- -1 alkynyl radical Chemical class 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 229950004535 rebamipide Drugs 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 208000007882 Gastritis Diseases 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006655 (C3-C8) heteroaryl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005281 alkyl ureido group Chemical group 0.000 abstract 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 125000005163 aryl sulfanyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 208000023652 chronic gastritis Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000005188 oxoalkyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000005494 xerophthalmia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Abstract
Se divulga una prodroga de rebamipida, un método para prepararla, y uso de la misma. También, se proporciona una composición farmacéutica que comprende la prodroga de rebamipida como un ingrediente activo. La prodroga de rebamipida es aumentada unas 25 veces en la tasa de absorción comparada con la rebamipida en sí misma, y puede ser aplicada para la profilaxis o tratamiento de úlcera gástrica, gastritis aguda, gastritis crónica, xeroftalmia, cáncer, osteoartritis, artritis reumatoidea, u obesidad. Reivindicación 1: Un compuesto, caracterizado porque se selecciona de entre un compuesto representado por la fórmula química (1), una sal farmacéuticamente aceptable del mismo, un isómero, hidrato o solvato, en donde, X es un átomo de oxígeno, un átomo de nitrógeno, o un átomo de azufre; e Y es un radical seleccionado del grupo que consiste en alquilo C₁₋₆, haloalquilo C₁₋₆, alquilo C₁₋₆(alquiloxi C₁₋₃), alquilo C₁₋₆(alqueniloxi C₂₋₆), alquilo C₁₋₆(alquilcarboniloxi C₁₋₆), alquilo C₁₋₆(alquilsulfanil C₁₋₆), alquilo C₁₋₆(arilsufanil), alquilo C₁₋₆(arilsulfonil), alquilo C₁₋₆(alquilamino C₁₋₆), alquilo C₁₋₆[(alquil C₁₋₆)(alquil C₁₋₆)amino], alquilo C₁₋₆[(alquil C₁₋₃)(aril)amino], alquilo C₁₋₆{[(alquil C₁₋₃)(aril)alquil C₁₋₃]amino}, alquilo C₁₋₆[(alquil C₁₋₃,)(heteroaril)amino], alquilo C₁₋₆(arilcarbonilamino), alquenilo C₂₋₆, alquinilo C₂₋₆, oxoalquilo C₂₋₆, cicloalquilo C₃₋₆, alquilo C₁₋₆(cicloalquil C₃₋₈), alquilo C₁₋₆(cicloalquenil C₃₋₈), alquilo C₁₋₆(heterocicloalquil C₃₋₈), alquilo C₁₋₆[(alquil C₁₋₆)heterocicloalquil C₃₋₈], alquilo C₁₋₆{[(alquil)alquil C₁₋₃]heterocicloalquil C₃₋₈}, alquilo C₁₋₆[(alquiloxicarbonil C₁₋₆)heterocicloalquil C₃₋₈], alquilo C₁₋₆[(alquiloxicarbonil C₁₋₃)heterocicloalquil C₃₋₈], alquenilo C₁₋₆(heterocicloalquil C₃₋₈), alquilo C₁₋₆[(alquil C₁₋₃)heterocicloalquenil C₃₋₈], alquilo C₁₋₆(aril), alquilo C₁₋₆[(alquil C₁₋₃)aril], alquilo C₁₋₆[(alquiloxi C₁₋₃)aril], alquilo C₁₋₆[(ariloxi)aril], alquilo C₁₋₆[(alquilsufanil C₁₋₃)aril], alquilo C₁₋₆[(alquiloxicarbonil C₁₋₃)aril], alquilo C₁₋₆[(ariloxicarbonil)aril], alquenilo C₃₋₆(aril), alquilo C₁₋₆(heteroaril), alquilo C₁₋₆[(alquiloxicarbonil)heteroaril], alquilo C₁₋₆[(alquil C₁₋₃)heteroaril C₃₋₈], alquilo C₁₋₆[(cicloalquil C₃₋₈)heteroaril], alquilo C₁₋₆[(aril)heteroaril], alquilo C₁₋₆[(alquil C₁₋₃)heteroaril], alquilo C₁₋₆{[(aril)alquil C₁₋₃]heteroaril}, alquilo C₁₋₆(alquiloxicarbonil C₁₋₆), alquilo C₁₋₆[(heterocicloalquil C₃₋₈)alquiloxicarbonil C₁₋₆], alquilo C₁₋₆(heterocicloalquilcarbonil C₃₋₈), alquilo C₁₋₆[(alquil C₁₋₃)heterocicloalquilcarbonil C₃₋₈], alquilo C₁₋₆[(alquil C₁₋₃)heterocicloalquilcarbonil C₃₋₈], alquilo C₁₋₆[(cicloalquil C₃₋₈)oxicarboniloxi], alquilo C₁₋₆[(heterocicloalquil C₃₋₈)oxicarboniloxi], alquilo C₁₋₆(ureído), alquilo C₁₋₆(arilureído), alquilo C₁₋₆[(aril)(alquilureído C₁₋₃)], alquilo C₁₋₆(alquilaminocarbonil C₁₋₆), alquilo C₁₋₆[(heterocicloalquil C₃₋₈)aminocarbonil], alquilo C₁₋₆{[(alquil C₁₋₃)heterocicloalquil C₃₋₈]aminocarbonil}, alquilo C₁₋₆[(alquil C₁₋₃)(alquiloxi C₁₋₃)aminocarbonil] y alquilo C₁₋₆(heterocicloalquil oxo C₃₋₈), con la condición de que el radical alquilo C₁₋₆, el radical alquenilo C₂₋₆, el radical alquinilo C₂₋₆, el radical oxoalquilo C₂₋₆, el radical cicloalquilo C₃₋₈, el radical cicloalquenilo C₃₋₈, el radical heterocicloalquenilo C₃₋₈, el radical arilo o el radical heteroarilo puedan substituirse con por lo menos un substituyente seleccionado del grupo que consiste en alquilo C₁₋₃, fluoro, cloro, bromo, hidroxi, oxo, nitro, y ciano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120068394 | 2012-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097226A1 true AR097226A1 (es) | 2016-03-02 |
Family
ID=49783488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102268A AR097226A1 (es) | 2012-06-26 | 2013-06-26 | Prodrogas de rebamipida, método para prepararlas y uso de las mismas |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11420963B2 (es) |
| EP (1) | EP2865669B1 (es) |
| JP (1) | JP6032451B2 (es) |
| KR (1) | KR101452277B1 (es) |
| CN (1) | CN104662004B (es) |
| AP (1) | AP2015008233A0 (es) |
| AR (1) | AR097226A1 (es) |
| AU (1) | AU2013281442B2 (es) |
| BR (1) | BR112014032627A8 (es) |
| CA (1) | CA2877853C (es) |
| CL (1) | CL2014003496A1 (es) |
| CO (1) | CO7240352A2 (es) |
| ES (1) | ES2875863T3 (es) |
| IL (1) | IL236479A0 (es) |
| MA (1) | MA37676B1 (es) |
| MX (1) | MX2015000023A (es) |
| NZ (1) | NZ704023A (es) |
| PE (2) | PE20160285A1 (es) |
| PH (1) | PH12015500172B1 (es) |
| RU (1) | RU2612509C2 (es) |
| SA (1) | SA113340675B1 (es) |
| SG (1) | SG11201408711PA (es) |
| TW (1) | TWI483727B (es) |
| UA (1) | UA113990C2 (es) |
| UY (1) | UY34882A (es) |
| WO (1) | WO2014003424A1 (es) |
| ZA (1) | ZA201500450B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| WO2016108319A1 (ko) * | 2015-01-02 | 2016-07-07 | 삼진제약 주식회사 | 신규 레바미피드 전구체의 염 및 이의 용도 |
| KR20170094584A (ko) * | 2016-02-11 | 2017-08-21 | 삼진제약주식회사 | 레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물 |
| KR102190019B1 (ko) * | 2018-10-23 | 2020-12-15 | 삼진제약주식회사 | 쇼그렌 증후군 예방 또는 치료용 조성물 |
| ES2913792T3 (es) * | 2019-09-03 | 2022-06-06 | Square Power Ltd | Rebamipida para uso en la profilaxis y el tratamiento de la enfermedad celíaca |
| EP3797773A1 (en) * | 2019-09-03 | 2021-03-31 | Square Power Ltd | Rebamipide for use in prophylaxis and treatment of cancer |
| CN111595985B (zh) * | 2020-07-09 | 2022-03-29 | 苏州正济药业有限公司 | 一种用hplc测定瑞巴派特有关物质的分析方法 |
| CN121039146A (zh) | 2023-04-27 | 2025-11-28 | 伊姆霍特克斯有限公司 | 作为nod2激动剂的去胞壁酰肽二酸及其用途 |
| WO2024224093A1 (en) | 2023-04-27 | 2024-10-31 | Imhotex Limited | Desmuramylpeptide dieesters as nod2 agonists and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI80022C (fi) * | 1982-07-05 | 1990-04-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat. |
| JPS6019767A (ja) | 1983-07-11 | 1985-01-31 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体を有効成分とする抗潰瘍剤 |
| JP3621463B2 (ja) * | 1995-04-26 | 2005-02-16 | 大塚製薬株式会社 | カルボスチリル誘導体ビスマス塩 |
| KR100669823B1 (ko) | 2001-02-20 | 2007-01-17 | 경동제약 주식회사 | 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체 |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| KR20040104020A (ko) | 2003-06-02 | 2004-12-10 | 진양제약주식회사 | 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제 |
| TWI363626B (en) * | 2004-11-15 | 2012-05-11 | Otsuka Pharma Co Ltd | Aqueous ophthalmic suspension of crystalline rebamipide |
| WO2006059781A1 (en) * | 2004-12-01 | 2006-06-08 | Otsuka Pharmaceutical Co., Ltd. | Improved process for preparing rebamipide |
| JP2008105970A (ja) | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | ジヒドロキノリン誘導体の製造方法及びその中間体 |
| WO2008074853A1 (en) * | 2006-12-21 | 2008-06-26 | Novartis Ag | Ophthalmic rebamipide solution |
| KR101032600B1 (ko) | 2008-08-11 | 2011-05-06 | 동우신테크 주식회사 | 고순도 레바미피드의 제조방법 |
| KR101182114B1 (ko) * | 2010-03-05 | 2012-09-12 | 한림제약(주) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 |
| CN102174015B (zh) | 2011-03-07 | 2013-10-16 | 江西同和药业有限责任公司 | 瑞巴派特的精制方法 |
-
2013
- 2013-06-24 SA SA113340675A patent/SA113340675B1/ar unknown
- 2013-06-26 NZ NZ704023A patent/NZ704023A/en not_active IP Right Cessation
- 2013-06-26 CN CN201380034373.4A patent/CN104662004B/zh not_active Expired - Fee Related
- 2013-06-26 TW TW102122678A patent/TWI483727B/zh not_active IP Right Cessation
- 2013-06-26 KR KR1020130073535A patent/KR101452277B1/ko not_active Expired - Fee Related
- 2013-06-26 PE PE2016000265A patent/PE20160285A1/es unknown
- 2013-06-26 SG SG11201408711PA patent/SG11201408711PA/en unknown
- 2013-06-26 MX MX2015000023A patent/MX2015000023A/es unknown
- 2013-06-26 AP AP2015008233A patent/AP2015008233A0/xx unknown
- 2013-06-26 AR ARP130102268A patent/AR097226A1/es unknown
- 2013-06-26 PE PE2014002534A patent/PE20150904A1/es not_active Application Discontinuation
- 2013-06-26 CA CA2877853A patent/CA2877853C/en active Active
- 2013-06-26 BR BR112014032627A patent/BR112014032627A8/pt not_active Application Discontinuation
- 2013-06-26 JP JP2015520012A patent/JP6032451B2/ja not_active Expired - Fee Related
- 2013-06-26 UA UAA201500494A patent/UA113990C2/uk unknown
- 2013-06-26 WO PCT/KR2013/005622 patent/WO2014003424A1/ko not_active Ceased
- 2013-06-26 RU RU2015102043A patent/RU2612509C2/ru active
- 2013-06-26 ES ES13809037T patent/ES2875863T3/es active Active
- 2013-06-26 UY UY0001034882A patent/UY34882A/es not_active Application Discontinuation
- 2013-06-26 US US14/411,390 patent/US11420963B2/en active Active
- 2013-06-26 MA MA37676A patent/MA37676B1/fr unknown
- 2013-06-26 AU AU2013281442A patent/AU2013281442B2/en not_active Ceased
- 2013-06-26 EP EP13809037.8A patent/EP2865669B1/en active Active
-
2014
- 2014-12-22 CL CL2014003496A patent/CL2014003496A1/es unknown
- 2014-12-25 IL IL236479A patent/IL236479A0/en unknown
-
2015
- 2015-01-22 ZA ZA2015/00450A patent/ZA201500450B/en unknown
- 2015-01-26 CO CO15014548A patent/CO7240352A2/es unknown
- 2015-01-26 PH PH12015500172A patent/PH12015500172B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097226A1 (es) | Prodrogas de rebamipida, método para prepararlas y uso de las mismas | |
| AR118341A2 (es) | Mezclas fungicidas ternarias | |
| MX377552B (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
| MX2014013660A (es) | Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b. | |
| CO7240428A2 (es) | Derivados de éster del ácido 2-aminonicotínico y bactericida que contiene el mismo como ingrediente activo | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| IN2014MN02106A (es) | ||
| CL2013003073A1 (es) | Compuestos derivados de pirrolotriazinona o imidazotriazinona, inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; utiles en el tratamiento de enfermedades respiratorias, inflamatorias, autoinmune, neurologica, cancer, entre otras. | |
| PE20200401A1 (es) | Nuevos compuestos como inhibidores de autotaxina y composiciones farmaceuticas que comprenden a los mismos | |
| CY1119422T1 (el) | Παραγωγα μπετουλινης | |
| MX350892B (es) | Síntesis de compuesto antiviral. | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| MX2016002185A (es) | Formulacion combinada de dos compuestos antivirales. | |
| IN2014CN04530A (es) | ||
| PH12015500008A1 (en) | Dimethyl-benzoic acid compounds | |
| BR112014032581A8 (pt) | inibidores de bifluorodioxalano-amino-benzimidazol quinase para o tratamento de câncer, distúrbios do snc e inflamação autoimune | |
| IN2014MN01521A (es) | ||
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| MX2021002588A (es) | Rapadocinas, inhibidores de transportador 1 de nucleosido equilibrador y usos de los mismos. | |
| AR086647A1 (es) | Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k | |
| AR096160A1 (es) | Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos | |
| PH12016500152A1 (en) | Novel triazine derivative | |
| MY185971A (en) | Pyranodipyridine compound | |
| MX354015B (es) | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |